RxDoctor Payments Data

Khaja Ahmed, MD

Nephrology · Torrance, CANPI 1033137633

Payments from drug & device makers

$463in general payments, 2019–2025

Across 10 payments — averaging $46.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$169
  • Bayer$125
  • Otsuka America Pharmaceutical, Inc.$96
  • Akebia Therapeutics Inc$25
  • Fresenius USA Marketing, Inc.$22
  • Calliditas Therapeutics US Inc.$14
  • plus $13 from 2 others

What the payments were for

  • Food & beverage$32771%
  • Education$13629%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$463 in reported general payments places this provider in the 30th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$131,117
Medicare patients
108
Services billed
566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol62$48,671
KerendiaFinerenone37$33,186
JardianceEmpagliflozin28$19,653
VeltassaPatiromer Calcium Sorbitex19$19,383
Sevelamer Carbonate75$16,187
LokelmaSodium Zirconium Cyclosilicate18$14,407
Calcium Acetate16$2,405
Nifedipine ErNifedipine19$1,589
Losartan Potassium103$1,378
Allopurinol42$1,307
Furosemide124$1,086
Atorvastatin Calcium62$904
Valsartan43$902
Hydralazine Hcl48$774
Calcitriol27$703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$169$63,07880 claims
BayerKerendia$125$33,18637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,341 nephrology providers in California.

Other nephrology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →